MedTrace Logo

Psychotropic Drug Use in the Elderly Living in Nursing Homes and the Influence of a Structured Drug Review

NCT03736577 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 224

Last updated 2021-02-16

No results posted yet for this study

Summary

The overall aim of this study is to explore if a structured drug review will change clinical symptoms and the psychotropic drugs prescription rate in the elderly living in nursing homes (participants of the study). The study will examine how training of nursing home physicians on reviewing prescription lists using the Norwegian general practice criteria - Nursing homes (NorGeP-NH) will influence the participants' clinical symptoms such as cognition, depression, anxiety and their quality of life. Secondary, we will analyse how a structured drug review will influence further psychotropic drug prescribing rates in nursing homes.

The hypothesis for this study are:

1. Training of nursing home physicians on doing a systematic drug review will decrease the participants' clinical symptoms and improve their Quality of Life.
2. A systematic drug review will decrease the psychotropic drug prescription rates compared to before the drug review.

Conditions

  • Cognitive Symptom
  • Depression
  • Anxiety
  • Neuropsychiatric Syndrome
  • Quality of Life
  • Activity of Daily Living
  • Physical Health
  • Drug Use

Interventions

OTHER

Drug reviews with NorGeP-NH

Physicians in the intervention group will attend a 1-2 hours lecture about psychopharmacology and drug review. They will learn how to do drug reviews with the Norwegian general practice criteria - Nursing homes (NorGeP-NH). The nursing home physicians will do the drug review on the participants' drug charts

Sponsors & Collaborators

  • Sykehuset Innlandet HF

    collaborator OTHER

  • The Dam Foundation

    collaborator OTHER

  • Norwegian Health Association

    collaborator OTHER

  • Ostfold Hospital Trust

    lead OTHER

Principal Investigators

  • Sverre Bergh, MD, PhD · Innlandet Hospital Trust, Postboks 104, 2381 Brumunddal, Norway

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-11-12
Primary Completion
2019-06-07
Completion
2019-06-07

Countries

  • Norway

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03736577 on ClinicalTrials.gov